Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion

Haematologica

Volumn 103, Issue 5, 2018, Pages 778-786

  Lagresle Peyrou, Chantal ^a,b,c   Lefrère, François ^a   Magrin, Elisa ^a   Ribeil, Jean Antoine ^a   Romano, Oriana ^b,c,d   Weber, Leslie ^b,c   Magnani, Alessandra ^a   Sadek, Hanem ^a,b,c   Plantier, Clémence ^a   Gabrion, Aurélie ^a   Ternaux, Brigitte ^a   Félix, Tristan ^b,c   Couzin, Chloé ^a   Stanislas, Aurélie ^a   Tréluyer, Jean Marc ^e   Lamhaut, Lionel ^c,e   Joseph, Laure ^a   Delville, Marianne ^a,b,c   Miccio, Annarita ^b,c   André Schmutz, Isabelle ^a,b,c   Cavazzana, Marina ^a,b,c   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b IMAGINE INSTITUTE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; FILGRASTIM; HEMOGLOBIN S; PLERIXAFOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTISICKLING AGENT; HETEROCYCLIC COMPOUND; HYDROXYUREA; PLERIXAFOR OCTAHYDROCHLORIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXCHANGE BLOOD TRANSFUSION; FLOW CYTOMETRY; GENE EDITING; GENE EXPRESSION; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RNA EXTRACTION; RNA SEQUENCE; SICKLE CELL ANEMIA; BLOOD TRANSFUSION; CASE CONTROL STUDY; CELL CULTURE; CLINICAL TRIAL; COHORT ANALYSIS; CYTOLOGY; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; PATHOLOGY; STEM CELL MOBILIZATION;

ANEMIA, SICKLE CELL; ANTI-HIV AGENTS; ANTIGENS, CD34; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CASE-CONTROL STUDIES; CELLS, CULTURED; COHORT STUDIES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; HYDROXYUREA;

EID: 85046350511     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2017.184788     Document Type: Article

References (36)

1. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311-323.
2. Walters MC, De Castro LM, Sullivan KM, et al. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2016;22(2):207-211.
3. Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548-1556.
4. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9): 848-855.
5. Cavazzana M, Ribeil JA, Lagresle-Peyrou C, Andre-Schmutz I. Gene therapy with hematopoietic stem cells: the diseased bone marrow's point of view. Stem Cells Dev. 2017;26(2):71-76.
6. Wang TF, Chen SH, Yang SH, Su YC, Chu SC, Li DK. Poor harvest of peripheral blood stem cell in donors with microcytic red blood cells. Transfusion. 2013;53 (1):91-95.
7. Constantinou VC, Bouinta A, Karponi G, et al. Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with beta-thalassemia major. Transfusion. 2017;57(4):1031-1039.
8. Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet. 1998;351(9107):959.
9. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood. 2001;97(10):3313-3314.
10. Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood. 2001;97(12):3998-3999.
11. Onitilo AA, Lazarchick J, Brunson CY, Frei- Lahr D, Stuart RK. Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc. 2003;35(8):3089-3092.
12. Kamble RT, Tin UC, Carrum G. Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease. Bone Marrow Transplant. 2006;37(11):1065-1066.
13. Rosenbaum C, Peace D, Rich E, Van Besien K. Granulocyte colony-stimulating factorbased stem cell mobilization in patients with sickle cell disease. Biol Blood Marrow Transplant. 2008;14(6):719-723.
14. Tormey CA, Snyder EL, Cooper DL. Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease. Transfusion. 2008;48(9):1930-1933.
15. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102(8): 2728-2730.
16. Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017;129(19):2680-2692.
17. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201(8):1307-1318.
18. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004;22(6):1095-1102.
19. Karponi G, Psatha N, Lederer CW, et al. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood. 2015;126(5): 616-619.
20. Ferrari G, Cavazzana M, Mavilio F. Gene therapy approaches to hemoglobinopathies. Hematol Oncol Clin North Am. 2017;31(5): 835-852.
21. Lionnet F, Arlet JB, Bartolucci P, et al. [Guidelines for management of adult sickle cell disease]. Rev Med Interne. 2009;30 (Suppl 3):S162-223.
22. Lamming CE, Augustin L, Blackstad M, Lund TC, Hebbel RP, Verfaillie CM. Spontaneous circulation of myeloid-lym-phoid-initiating cells and SCID-repopulating cells in sickle cell crisis. J Clin Invest. 2003;111(6):811-819.
23. Doulatov S, Notta F, Eppert K, Nguyen LT, Ohashi PS, Dick JE. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol. 2010;11(7):585-593.
24. Six EM, Bonhomme D, Monteiro M, et al. A human postnatal lymphoid progenitor capable of circulating and seeding the thymus. J Exp Med. 2007;204(13):3085-3093.
25. Handgretinger R, Kuci S. CD133-positive hematopoietic stem cells: from biology to medicine. Adv Exp Med Biol. 2013;777:99-111.
26. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy. 2009;11(4):464- 471.
27. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 2012;20(1):230-238.
28. Richard RE, Siritanaratkul N, Jonlin E, Skarpidi E, Heimfeld S, Blau CA. Collection of blood stem cells from patients with sickle cell anemia. Blood Cells Mol Dis. 2005;35(3):384-388.
29. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317-1322.
30. Alvarez-Larran A, Perez-Encinas M, Ferrer- Marin F, et al. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica. 2017;102(1):103-109.
31. Halter J, Kodera Y, Ispizua AU, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009;94(1):94-101.
32. Lack NA, Green B, Dale DC, et al. A phar-macokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther. 2005;77(5):427-436.
33. To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118(17):4530-4540.
34. Lefrere F, Mauge L, Rea D, et al. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure. Transfusion. 2013;53(3):564-569.
35. Pantin J, Purev E, Tian X, et al. Effect of high-dose plerixafor on CD34(+) cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102(3):600-609.
36. Weisser M, Demel UM, Stein S, et al. Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions. J Allergy Clin Immunol. 2016;138(1):219-228.e219.